Amelioration of Lipid Profile Through Date Cider-vinegar Along With 5:2 Intermittent Fasting

July 14, 2026 updated by: Maria Aslam, University of Lahore

Amelioration of Lipid Profile Through Date Cider-vinegar Along With 5:2 Intermittent Fasting Among Prediabetic Individuals

A common metabolic abnormality in hyperglycemic individuals, dyslipidemia is strongly linked to an increased risk of cardiovascular illness. This study looked at how date cider vinegar and 5:2 intermittent fasting affected the lipid profile and metabolic indices of hyperglycemic patients

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The target population was adults between the ages of 35 and 65 years who are receiving outpatient care at a hospital or clinic with a diagnosis of either mild to moderate hypertension, dyslipidemia or pre-diabetes. Once consent was given, participants were then be randomly assigned to receive the prescribed intervention or act as a control. The intervention period was 12 weeks.

Participants in the experimental groups received date cider vinegar supplementation, with one group additionally following the 5:2 intermittent fasting protocol. The control group received standard dietary advice without vinegar supplementation or fasting intervention. Participants were instructed to follow the assigned intervention daily according to the study protocol. Weekly follow-up visits were conducted to monitor dietary compliance, record self-reported adherence, and assess health outcomes including lipid profile, body weight,and blood pressure. Usual dietary intake was also monitored to ensure consistency and adherence to the intervention.

At baseline, nutritional assessment based on weight and height, BMI, waist circumference, blood pressure, fasting blood glucose, lipid panels (HDL, LDL, total cholesterol, triglycerides), and dietary intake analysis were done. After 12 weeks of intervention all the measurements that were done again to compare the results pre- and post-intervention.

Study Type

Interventional

Enrollment (Actual)

108

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • The University of Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • The inclusion criterion was target adults with both gender aged 35-65 years.
  • Adults with a diagnosis of mild to moderate hypertension
  • Mild hypertension (140-159/90-99 mm Hg)
  • Moderate hypertension (160-179/100-109 mm Hg)
  • Adults having mild to moderate alterations in lipid profile
  • Triglycerides: 150 to 499 mg/dL
  • LDL-C levels: Mild Alteration (130 to 159 mg/dL) and Moderate Alteration (160 to 189 mg/dL)
  • Adults with pre-diabetes (hbA1c= 5.6-6.4%) were used.
  • Patients were solicited from hospital.

Exclusion Criteria:

  • Any Lactating and pregnant women were not included.
  • Any person allergic to citric acid.
  • Adults suffering from critical health conditions, including cancer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Group (T 0 )
Participants continued their prescribed conventional medications for hyperglycemia and lipid management without any additional dietary or vinegar intervention for a duration of 3 months.
Drug: Control Group (T 0 )
The control group received standard dietary advice without vinegar supplementation or fasting intervention.
Experimental: Experimental Group (T 1 )
Participants received Date Cider Vinegar (DCV) for a duration of 3 months.
Dietary supplement: Experimental Group (T 1 )
Participants were advised to take 15 ml of Date Cider Vinegar (DCV) diluted in 1 cup (250ml) of water 15 minutes before breakfast and dinner daily for a duration of 3 months.
Experimental: Experimental Group (T 2 )
Participants followed 5:2 Intermittent Fasting (two non-consecutive fasting days per week) along with DCV intervention for a duration of 3 months.
Combination product: Experimental Group (T 2 )

Participants were advised to follow 5:2 Intermittent Fasting (two non-consecutive fasting days per week) along with DCV intervention for a duration of 3 months.

15 ml of DCV was diluted in 1 cup of water and It was taken 15 minutes before breakfast and dinner daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Mass Index
Time Frame: 3 months
BMI was calculated by dividing weight (in kg) by the square of height (in meters).
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure
Time Frame: 3 months
Blood pressure measurements will be taken using an automated sphygmomanometer, with systolic pressure and diastolic pressure being measured while sitting after a 5-minute rest. The average of three readings were used for analysis.
3 months
Lipid Profile
Time Frame: 3 months
Total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein cholesterol (HDL-C) levels were measured using enzymatic methods with commercial test kits.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Lahore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 12, 2026

Primary Completion (Actual)

April 12, 2026

Study Completion (Actual)

May 12, 2026

Study Registration Dates

First Submitted

July 14, 2026

First Submitted That Met QC Criteria

July 14, 2026

First Posted (Actual)

July 17, 2026

Study Record Updates

Last Update Posted (Actual)

July 17, 2026

Last Update Submitted That Met QC Criteria

July 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-UOL-FAHS/573/2026

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabete Mellitus

Clinical Trials on Control Group (T 0 )

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe